foto

Prof. dr. M.J. Kersten MD

Position
Professor
Main activities
Patient care, Research
Specialisation
Biology and treatment of lymphoma, with an emphasis on early clinical trials
Focus of research

Marie José Kersten is a professor of hematology and head of the department of Hematology at the Academic Medical Center in Amsterdam. B cell malignancies are the main focus of research in this department, which together with the departments of Pathology and Experimental Immunology forms the basis for the LYMMCARE Institute (Lymphoma and Myeloma Center Amsterdam). Marie José Kersten is involved in several research projects and she is the principal investigator for several phase I/II clinical trials focusing on the biology and treatment of NHL, Waldenstrom’s macroglobulinemia and Hodgkin lymphoma. She has recently been appointed as chair of the newly established EHA (European Hematology Association) Scientific Working Group Lymphoma. She is the co-chair of the HOVON (Hemato-Oncologie Volwassenen Nederland) Lymphoma Working Party, and a co-founder and member of the Board of the Lunenburg Lymphoma Phase I/II Consortium (LLPC). The main focus of the LLPC is to perform early clinical trials (from first-in-man trials to early phase II trials) in patients with lymphoma. She is also an active member of the Lunenburg Lymphoma Biomarker Consortium (LLBC), the European Waldenstrom’s Macroglobulinemia Consortium (EWMC) and the HOVON Myeloma Working Party. Another research theme within LYMMCARE is to better understand the biology underlying tumor growth, progression and treatment resistance (in lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma). This research is done in collaboration with the pathology department at the AMC (Pals/Spaargaren).
 

Key publications
  • Vermaat JS, Pals ST, Younes A, Dreyling M, Federico M, Aurer I, Radford J, Kersten MJ, Precision medicine in diffuse large B-cell lymphoma: hitting the target. HAEMATOLOGICA 2015;100 (8):989-993 [PubMed]
  • Kersten MJ , Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST, Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. BLOOD CANCER J 2014;4:e266 [PubMed]
  • Mank APM, Schoonenberg C, Bleeker K, Heijmenberg S, Heer Kd, van Oers MHJ, Kersten MJ, Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care. LEUKEMIA LYMPHOMA 2015;56 (7):2098-2104 [PubMed]
  • Hommes DW, Duijvestein M, Zelinkova Z, Stokkers PCF, Ley MHd, Stoker J, Voermans C, van Oers MHJ, Kersten MJ, Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. J CROHNS COLITIS 2011;5 (6):543-549 [PubMed]
  • Thijssen R, ter Burg J, van Bochove GGW, de Rooij MFM, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MHJ, Eldering E, Kersten MJ , Kater AP, The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. LEUKEMIA 2016;30 (2):337-345 [PubMed]
All Publications
Research programmes

Biology and treatment of lymphoma

Lymphoma is a malignancy of the immune system, resulting from genetic alterations in the lymphoma cells and supported by signals originating from the microenvironment (in the lymph node or bone marrow). With immunochemotherapy, approximately 50% of patients can be cured. Better understanding the biology of lymphoma has resulted in several new treatment options, such as specific kinase inhibitors, antibody drug conjugates and chimeric antigen receptor T cells. The major aims of the research of MJ Kersten are 1. To investigate novel treatments. To this aim a national phase I/II consortium has been established, leading to the availability of novel therapeutic treatment options for lymphoma patients in the Netherlands. MJ Kersten is the principal investigator for several international phase I/II trials (in Hodgkin lymphoma, follicular lymphoma and Waldenstrom's macroglobulinemia). Linked to these clinical studies is a translational research program aiming to better understand response and resistance to these novel agents. Furthermore, she has established a biobank for samples of patients with WM. 2. To better understand the biology underlying tumor growth, progression and treatment resistance (in lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma). This research is done in collaboration with the pathology department at the AMC (Pals/Spaargaren).
 

Faculty
Prof. dr. M.J. Kersten MD

PhD Students
J. Driessen BSc
H.C.E.R.E.J. Lantermans
Y.F. van Lier
M. Minderman
Drs. M.L. Nijland
S.Z. Omar
Drs. W.S. Stevens (VUMC)

Prof. dr. M.H.J. van Oers (Pathogenesis and Immunotherapy of B cell malignancies)

Current research funding
  • Acerta Pharma B.V.
  • Celgene Corporation
  • Chiltern International BV
  • Covance CAPS Ltd.
  • Crediteurenadm. VUmc, p/a Profource Service Center
  • GlaxoSmithKline BV
  • Janssen Cilag B.V.
  • Kite Pharma, Inc.
  • Millennium Pharmaceuticals, Inc.
  • NIEUWE DEB SO
  • Novartis Pharma BV
  • PAREXEL International (IRL) Limited
  • Pharm-Olam International CRA
  • Stichting AMC Foundation
  • Stichting Hematologisch Oncologische Wetenschap
  • Stichting Hovon Amsterdam, p/a VUmc
  • VUmc Research B.V.